glp-1 agonist and grapefruit GLP1 Receptor Agonists—Effects beyond Obesity Diabetes Dual and Triple Gut Peptide

This category of drugs is likely to continue to gain FDA approval for additional indications

[DOI] [PMC free article] [PubMed] [Google Scholar] 501.Irie S., Matsumura Y., Zdravkovic M., Jacobsen L.V., Kageyama S

It produces more modest results than semaglutide or tirzepatide, typically around 8 percent body weight loss, but it was the first GLP-1 to receive FDA approval specifically for weight management and remains a viable option for patients who prefer a shorter-acting medication or who experience intolerable side effects on the more potent formulations

A Reuters analysis of earnings transcripts revealed that mentions of GLP-1 and related terms doubled from 127 in Q2 2023 to 256 mentions in Q3 across 29 U.S

Unlike phentermine, every major GLP-1 medication carries FDA approval for long-term use